TY - JOUR
T1 - The Long-term impact of oxaliplatin chemotherapy on rodent cognition and peripheral neuropathy
AU - Fardell, Joanna E.
AU - Vardy, Janette
AU - Monds, Lauren A.
AU - Johnston, Ian N.
PY - 2015/9/15
Y1 - 2015/9/15
N2 - Chemotherapy treatment is associated with cognitive dysfunction in cancer survivors after treatment completion. The duration of these impairments is unclear. Therefore this paper aims to evaluate the lasting impact of varying doses of the chemotherapy oxaliplatin (OX) on cognition and peripheral neuropathy. In Experiment 1 rats were treated once a week for 3 weeks with either physiological saline (control) or 6. mg/kg OX i.p. and were assessed for peripheral neuropathy, using von Frey filaments, and cognitive function, using novel object and location recognition, up to 2 weeks after treatment completion. For Experiment 2 rats received 3 weekly i.p. injections of either physiological saline (control), 0.6. mg/kg, 2. mg/kg or 6. mg/kg OX and assessed for peripheral neuropathy and cognitive function up to 11 months after treatment completion. Systemic OX treatment induced lasting effects on cognitive function at 11 months after treatment, and peripheral neuropathy at 1 month after treatment and these were dose dependent; higher doses of OX resulted in worse cognitive outcomes and more severe peripheral neuropathy.
AB - Chemotherapy treatment is associated with cognitive dysfunction in cancer survivors after treatment completion. The duration of these impairments is unclear. Therefore this paper aims to evaluate the lasting impact of varying doses of the chemotherapy oxaliplatin (OX) on cognition and peripheral neuropathy. In Experiment 1 rats were treated once a week for 3 weeks with either physiological saline (control) or 6. mg/kg OX i.p. and were assessed for peripheral neuropathy, using von Frey filaments, and cognitive function, using novel object and location recognition, up to 2 weeks after treatment completion. For Experiment 2 rats received 3 weekly i.p. injections of either physiological saline (control), 0.6. mg/kg, 2. mg/kg or 6. mg/kg OX and assessed for peripheral neuropathy and cognitive function up to 11 months after treatment completion. Systemic OX treatment induced lasting effects on cognitive function at 11 months after treatment, and peripheral neuropathy at 1 month after treatment and these were dose dependent; higher doses of OX resulted in worse cognitive outcomes and more severe peripheral neuropathy.
KW - oxaliplatin
KW - chemotherapy
KW - cognition
KW - rat
KW - peripheral neuropathy
KW - mechanical allodynia
UR - http://www.scopus.com/inward/record.url?scp=84930194747&partnerID=8YFLogxK
U2 - 10.1016/j.bbr.2015.04.038
DO - 10.1016/j.bbr.2015.04.038
M3 - Article
C2 - 25934489
SN - 0166-4328
VL - 291
SP - 80
EP - 88
JO - Behavioural Brain Research
JF - Behavioural Brain Research
ER -